Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570621 | 0.84 | TACR3 (0.39) | ADORA3ADORA2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3574026 | 0.84 | CTSK (0.42) | GAASMN1; SMN2 | |
| SCHEMBL3562759 | 0.84 | CDK9 (0.40) | MEN1GAAKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL3571502 | 0.83 | CTSK (0.44) | GAA | |
| SCHEMBL3569022 | 0.77 | GPR39 (0.41) | SYKMEN1KMT2A | |
| SCHEMBL3572008 | 0.74 | SMN1; SMN2 (0.35) | MEN1GAAKMT2ASMN1; SMN2TACR3 | |
| Pyridine SCHEMBL3566017 | 0.71 | JAK2 (0.33) | SYKTAS1R3TAS1R1MAPK1 | |
| SCHEMBL3559302 | 0.71 | TACR3 (0.41) | GAATACR3 | |
| SCHEMBL3566255 | 0.71 | ALDH1A1 (0.41) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3566316 | 0.71 | AXL (0.41) | MEN1GAAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633363-B1 | PYRIDINYL ACETONITRILES | MERCK SERONO SA (CH) | 2012-11-07 | — | — | EP | claimed |
| US-7855212-B2 | Pyridinyl acetonitriles | MERCK SERONO SA (CH) | 2010-12-21 | — | — | US | claimed |
| US-20070060594-A1 | Pyridinyl acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060594-A1 | Pyridinyl acetonitriles | GSK3B, GSK3A, MAPK3 | SYK 823/4885ADORA3 1328/4885ADORA2A 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.